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OBJECTIVE—Cystic ﬁbrosis (CF)-related diabetes (CFRD) is associated with declining pul-
monary function and increased mortality. During oral glucose tolerance testing (OGTT), CFRD
is deﬁned by 2-h plasma glucose (PG2). We hypothesized PG elevations during OGTT resolving
by 2 h, not meeting CFRD criteria, inﬂuence pulmonary function in CF. Thus we investigated
the frequency of elevated 1-h OGTT PG (PG1) and its relationship with pulmonary function.
RESEARCHDESIGNANDMETHODS—RetrospectivereviewofOGTTswasperformed
between August 2005 (annual screening initiation) and June 2008 at Children’s Hospital of
PhiladelphiaCFCenter.First-time,wellstateOGTTs(PG0,PG1,PG2)wereanalyzed.Additional
data collected were: percent predicted forced expiratory volume in 1 s (FEV1), BMI percentile,
lungbacterialcolonization,age,andsex.OGTTswerecategorizedasnormal(PG2,140mg/dL),
impaired glucose tolerance (IGT) (PG2 140–199 mg/dL), CFRD (PG2 $200 mg/dL), and in-
determinate glycemia (INDET) (PG1 $200 mg/dL and PG2 ,140 mg/dL). Frequency of PG1
$140 but ,200 mg/dL was also noted. Multivariable linear regression was used to assess asso-
ciations between percent predicted FEV1, BMI percentile, and OGTT PG.
RESULTS—OGTTs (101) were available (59 male/42 female; age 5.8–22 years, percent
predicted FEV1 =9 4 . 56 18%, BMI percentile = 52 6 25%). With the use of PG2, 91 OGTT
were normal, eight were IGT, and two were CFRD. With the use of PG1 (n =8 9 ) ,3 9O G T T
were normal, 36 were PG1 $140 ,200 mg/dL, and 14 were PG1 $200 mg/dL. PG1 was
negativelyassociatedwithpercentpredictedFEV1,adjustingforBMIpercentile(P =0.009,R
2
0.13). Percent predicted FEV1 was not associated with PG0, PG2, age, sex, or lung bacterial
colonization.
CONCLUSIONS—PG elevations at nontraditional OGTT times are common in CF. The
association of increasing PG1 with worse pulmonary function suggests early PG abnormalities
maybedeleteriousoranearlymarkerforworseningdiseaseandwillbemissedifCFRDdiagnosis
focuses on PG2.
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W
ith improved survival among in-
dividuals with cystic ﬁbrosis (CF),
diabetes mellitus has emerged as a
signiﬁcant comorbidity. The CF Founda-
tion Patient Registry 2008 Annual Data
Report,w h i c hr e ﬂects data from over
25,000 patients at U.S.-accredited CF
care centers, reports that 20% of indi-
viduals with CF will have CF-related di-
abetes (CFRD) by the third decade (1).
Higher prevalence of 40–50% has been
reported in adults with CF followed at
the University of Minnesota, where rou-
tine annual screening has been in place
since the early 1990s (2). CFRD is associ-
ated with worse clinicalstatus, as indicated
by reduced pulmonary function; increased
frequency of pulmonary exacerbations;
increased prevalence of important sputum
pathogens such as Pseudomonas aeruginosa
and Burkholderia cepacia;a n dw o r s e n i n g
nutritional status, among others (3). Fur-
ther highlighting its clinical signiﬁcance,
CFRD is associated with increased mor-
bidity and up to a sixfold greater mortal-
ity rate (2,4).
CFRD is hypothesized to result pri-
marily from insulin deﬁciency, although
some element of insulin resistance is
likely present as well. Before the develop-
ment of frank diabetes, insulin secretion
is delayed and blunted (5). The earliest
changes in glucose tolerance involve vari-
able postprandial hyperglycemia. Pro-
gressive decline in insulin secretion leads
to impaired glucose tolerance (IGT) and,
ultimately, CFRD.
The oral glucose tolerance test
(OGTT) is recommended for screening
purposes (6), and the diagnostic criteria
for CFRD are similar to those for other
formsofdiabetes.However,theappropri-
ateness of using conventional thresholds
derived from epidemiologic studies in
non-CF patients for the diagnosis of
CFRD has been questioned (7). In type
2 diabetes, glycemic thresholds deﬁning
diabetes are based on glucose concentra-
tions associated with microvascular com-
plications, such as diabetic retinopathy
andnephropathy(8).Althoughmicrovascu-
lar complications are relevant in CF (9), the
paradigm for deﬁning glucose abnormalities
in CF is shifting to focus on outcomes more
immediately relevant to CF, such as nutri-
tional status and pulmonary function. This
paradigm shift is underscored by a recent
randomized control trial in which insulin
treatmentwasassociatedwithimprovednu-
tritional status in adults with CFRD without
fasting hyperglycemia (10).
In 2009, the North American CFRD
Consensus Committee restructured glu-
cose tolerance categories in CF, based on
the fasting and 1- and 2-h plasma glucose
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ORIGINAL ARTICLEduring an OGTT (6): normal glucose tol-
erance (NGT), IGT, CFRD, and indeter-
minate glycemia (INDET). This new
category of INDET occurs in individuals
with normal fasting and 2-h plasma glu-
cose but who have 1-h plasma glucose
concentrations greater than 200 mg/dL
(6). The clinical relevance of this INDET
category with regard to clinical outcome
in CF is not known.
The goals of this study were to in-
vestigate the frequency of abnormal 1-h
plasma glucose during an OGTT and to
explore the relationship between the 1-h
plasma glucose (PG1), percent predicted
forced expiratory volume in 1 s (FEV1),
and BMI percentile in a pediatric CF pop-
ulation. We hypothesized that elevations
in PG1 would be both common and neg-
atively associated with percent predicted
FEV1 and BMI percentile. Our data sug-
gest that elevations of PG1 are in fact as-
sociated with worse clinical outcomes in
CF and provide a foundation for further
investigation regarding optimal manage-
ment of CFRD.
RESEARCH DESIGN AND
METHODS
Subjects
InAugust2005,TheChildren’sHospitalof
Philadelphia CF Center initiated annual
CFRD screening in children over age 6–8
years using a standard OGTT (75 g/kg
dextrose, maximum dose 75 g) after an
overnight fast. This retrospective chart re-
viewislimitedtoOGTTperformedforthe
ﬁrst time in individual subjects between
August 2005 and June 2008 in the well
state, deﬁned as no hospitalizations or
oral or intravenous glucocorticoid ex-
posure within 6 weeks before OGTT.
Patients that had undergone lung trans-
plant or had a previous diagnosis of
CFRD were excluded. Patients who were
unabletocooperatewithpulmonaryfunc-
tion testing because of young age or
behavioral/developmental issues were ex-
cluded from the analyses examining asso-
ciations between OGTT and pulmonary
function.
Data
Data were collected from clinical records
and Port CF and included OGTT plasma
glucoseconcentrations,percentpredicted
FEV1 and percent predicted forced vital
capacity (FVC) according to the Wang-
Hankinson reference equations (REF),
and BMI percentile. Sputum cultures
to assess bacterial colonization were
performed on spontaneously expecto-
rated sputum (when available) or by
cough swabs. All of these evaluations
were performed as part of standard clini-
cal care at the time of the OGTT.
OGTT results were categorized ac-
cording to PG2 as normal (PG2 ,140
mg/dL), IGT (PG2 140–199 mg/dL), and
CFRD (PG2 $200 mg/dL), as well as ac-
cording to PG1 as INDET (PG1 $200
mg/dL but PG2 ,140 mg/dL or PG1
$140 mg/dL but ,200 mg/dL).
Statistical methods
Means and SD were calculated for con-
tinuous variables; proportions were used
to characterize categorical data. Simple
linear regression was used to test the
associations between OGTT PG, as a con-
tinuousvariable,andpulmonaryfunction
tests, BMI percentile, and other clinical
f a c t o r ss u c ha ss e x ,a g e ,a n ds p u t u m
bacterial colonization. Multivariable lin-
ear regression was then used to test the
associations between OGTT PG and
percent predicted FEV1 after adjustment
for BMI percentile. The regression mod-
els were assessed further through the
Shapiro-Wilk test of normality of the re-
siduals and the Cook-Weisberg test for
heteroscedasticity.
Data analysis was performed using
Stata 9 (Stata Corporation, College Sta-
tion, TX). Two-sided tests of hypotheses
wereused,andaP,0.05wasconsidered
statistically signiﬁcant.
This study was approved by the In-
stitutional Review Board at The Children’s
Hospital of Philadelphia.
RESULTS—During 2005 through
2008, ﬁrst-time OGTT were performed
in101childrenwithCF.CompleteOGTT
data (PG0, PG1, PG2) were available in
89 subjects.
Clinical characteristics of the 101
(42F) are listed in Table 1. Mean age
was 12.5 6 3.9 years. Mean BMI percen-
tile was 52 6 25%, and mean percent
predicted FEV1 was 94.5 6 18%. Mean
PG0, PG1, and PG2 were 86 6 9 mg/dL,
148 6 51 mg/dL, and 102 6 32 mg/dL,
respectively.
Ofthe101whounderwentOGTT,14
(14%) had PG1 $200 mg/dL. Of this
group, nine (64%) had normal PG2
(,140 mg/dL) and, until recently, would
have been labeled as having normal glu-
cosetolerance.Twoofthese14hadCFRD
(PG2 $200 mg/dL), and an additional
three of these 14 had IGT (Fig. 1). An
additional 36 had PG1 $140 but ,200
mg/dL.
Simple linear regression analysis was
performed to test for associations be-
tween percent predicted FEV1, percent
predicted FVC, and BMI percentile and
age, sex, PG0, PG1, and PG2 as well as
between BMI percentile and pulmonary
function tests. As shown in Table 2, per-
cent predicted FEV1 and percent pre-
dicted FVC were associated with both
BMI percentile and PG1 but not age,
sex, PG0, PG2, or colonization status in
this unadjusted analysis. BMI percentile
was also associated with PG1.
We performed multivariable linear
regression analyses to adjust for potential
confounders (Table 2); PG1 remained
negatively associated with percent pre-
dicted FEV1 even after adjustment for
BMI percentile. This relationship did not
persistforpercentpredictedFVCafterad-
justment for BMI percentile. Accordingto
theregressionmodel,afteradjustmentfor
BMI percentile, percent predicted FEV1
was reduced by 1% for every 10 mg/dL
increase in PG1.
CONCLUSIONS—In children with
CF undergoing routing OGTT for CFRD
screening, the 1-h PG is commonly ele-
vated despite normal fasting and 2-h PG
concentrations. In fact, until the recent
introduction of the INDET category of
glucose tolerance in CF, ;10% of our
center’s pediatric CF population would
have been labeled as having normal glu-
cose tolerance despite anelevatedPG1,or
1-h PG. More importantly and likely clin-
ically relevant, our data suggest that the
1-h OGTT PG is negatively associated
with percent predicted FEV1 even after
adjustment for BMI percentile. In con-
trast, fasting and 2-h PG concentrations,
parameters upon which we typically rely
Table 1—Patient characteristics
Characteristic All (n =1 0 1 )
Female/male 42/59
Age (years) 12.5 6 3.9
White 99 (98%)
BMI percentile 52% 6 25
Percent predicted FEV1 94.5% 6 18.3
Percent predicted FVC 98.7% 6 16.8
MSSA or MRSA 23
Burkholderia cepacia 4
Pseudomonas aeruginosa 24
Data are mean 6 SD. MSSA, methicillin-sensitive
Staphylococcus aureus; MRSA, methicillin-resistant
Staphylococcus aureus.
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Brodsky and Associatesto deﬁne abnormal glucose, were related
to neither BMI percentile nor pulmonary
function. These data suggest that clini-
cally important abnormal PG elevations
may be missed if glucose tolerance testing
omitsevaluationofPG1andoptimalther-
apy may require additional focus on nor-
malizing PG1.
A similar model for redeﬁning glucose
abnormalitiespredicatedonnontraditional
outcomes can be seen with gestational
diabetes. The original deﬁnitions of glu-
cose abnormalities acquired during preg-
nancy were based upon subsequent
development of diabetes and not upon
predictive value for adverse pregnancy
outcomes. Recently, the Hyperglycemia
and Adverse Pregnancy Outcome study
identiﬁed an association between mater-
nal glucoseconcentrations and markers of
perinatal complications, even at glucose
concentrations below those traditionally
accepted as diagnostic of gestational di-
abetes (11). Additionally, the ﬁnding of
improved pregnancyoutcomeswithtreat-
mentofmildgestationaldiabetes (12)em-
phasizes importance of the 1-h PG. An
abnormal PG1 predicts postpartum meta-
bolic dysfunction (13) and has been asso-
ciated with increased risk for adverse fetal
outcomessuch as large for gestationalage,
neonatal hypoglycemia, increased rate of
cesarean section, and shoulder dystocia
(11).
Elevations of PG1 are also associated
with abnormalities in inﬂammatory
markers and metabolic characteristics
in patients without a diagnosis of diabe-
tes. Adults with PG1 .155 mg/dL had
signiﬁcant increases in inﬂammatory
markers and lipid ratios, higher white
blood cell count and ﬁbrinogen levels,
and worse insulin sensitivity (14). More-
over, subjects with normal glucose toler-
anceasdeﬁned byfastingand2-hPG,but
whohadPG1.155mg/dL,hadaﬁvefold
greater risk of type 2 diabetes than those
subjects with PG1 ,155 mg/dL (15).
These ﬁndings further highlight the im-
portanceofunderstandingtheroleofhy-
perglycemia that occurs earlier than the
2-h mark.
Both CFRD and IGT are associated
with greater declines in pulmonary func-
tion (16). Glucose abnormalities occur-
ring earlier than 2 h during a OGTT
have also been associated with declines
in weight in the year preceding the
OGTT (17). More concerning, CFRD is
associated with increased mortality (2).
Recent data from the University of Min-
nesota suggest, however, that early diag-
nosisandtreatmentofCFRDcanimprove
survival (2). In a 1-year randomized con-
trol trial of CFRD without fasting hyper-
glycemia, insulin treatment improved
BMI percentile, and, although not statis-
tically signiﬁcant, trends in reversing
declines in pulmonary function were sug-
gested.
Current recommendations for the
treatment of blood glucose abnormalities
in CF rely on the 2-h blood glucose
concentration, which is deﬁned as abnor-
mal based upon its ability to predict
development of microvascular complica-
tions. In the setting of CF, worsening
pulmonary function and poor nutritional
status are the more clinically relevant
causes of signiﬁcant morbidity and mor-
tality. Given that current median pre-
dicted survival for people with CF is
only ;37 years, pulmonary function
andnutritionalstatus eclipse microvascu-
lar disease as clinically signiﬁcant causes
of morbidity and mortality in CF. Thus
our ﬁndings of worse percent FEV1 in
the setting of increasing PG1 but not
PG2 suggest earlier and not typically as-
sessed glucose abnormalities may have
implications for pulmonary status and
that reliance on PG2 may miss an impor-
tant impetus for intervention.
In this study, a negative association
between PG1 and baseline percent FEV1
was identiﬁed; however, this association
Table 2—Unadjusted associations between OGTT and pulmonary function and BMI
Variable
Partial b-coefﬁcient (95% CI) P value R
2 Dependent Independent
Unadjusted
Percent predicted FEV1 PG1 20.11 (20.18 to 20.04) ,0.0003 0.10
BMI percentile 0.19 (0.05–0.33) 0.007 0.07
Percent predicted FVC PG1 20.06 (20.13 to 0.005) 0.07 0.04
BMI percentile 0.19 (0.06–0.32) 0.004 0.08
BMI percentile PG1 20.11 (20.21 to 20.005) 0.04 0.05
Adjusted for BMI percentile
Percent predicted FEV1 0.13
PG1 20.10 (20.17 to 20.02) 0.009
BMI percentile 0.14 (20.01 to 0.29) 0.067
Percent predicted FVC 0.1
PG1 20.05 (20.11 to 0.02) 0.2
BMI percentile 0.18 (0.04–0.32) 0.01
Figure 1—Plasma glucose excursions during OGTT.
294 DIABETES CARE, VOLUME 34, FEBRUARY 2011 care.diabetesjournals.org
One-hour plasma glucose and pulmonary functiondoes not differentiate between 1) a causal
effect and 2) glucose abnormalities and
worsening percent FEV1,b o t ha r i s i n ga s
manifestations of worsening CF disease.
In fact, PG1 may only be an early marker
of pulmonary decline. It is important to
also note that although the model is sta-
tistically signiﬁcant, the R
2 was low; an
association between glucose abnormali-
ties is therefore suggested, but the clinical
impact of this association has yet to be
determined. The ﬁnding of increasing
PG1 predicting worse percent FEV1 in
subsequent years would provide support
for this causal effect, while an interven-
tion study targeting the 1-h OGTT blood
glucosewouldprovideimportantinsights
into the role of glucose/insulin in nutri-
tional status and pulmonary function.
We have identiﬁed a signiﬁcant asso-
ciation between elevated PG1 and de-
creased percent predicted FEV1 in
childrenwithCF.Theseﬁndingssupporta
new paradigm for the approach to PG ab-
normalities in CF by deﬁning PG abnor-
malities by risk of pulmonary function
decline and nutritional status compromise
rather than microvascular complications,
as well as support further investigation of
glycemic control deﬁned by PG1 in CF.
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